Why is Gland Pharma falling/rising?

As of 02-Sep, Gland Pharma Ltd's stock price is currently at 1,860.40, reflecting a decrease of 11.6 points or 0.62%. The stock has been underperforming, having fallen consecutively for the last two days with a total decline of 1.31%. In the past week, the stock has decreased by 3.42%, and over the past month, it has seen a decline of 6.00%. Additionally, the stock's delivery volume has significantly decreased by 68.25% compared to the five-day average, indicating falling investor participation. Despite these challenges, the company has a low debt-to-equity ratio and has reported strong financial results, including record net sales and profit before tax in the latest quarter, which may provide some support for the stock.
Broader market context shows that Gland Pharma's recent performance has been weaker than the benchmark Sensex, which has only declined by 0.78% over the past week. While Gland Pharma has shown positive year-to-date returns of 4.01%, its longer-term performance is concerning, with a 27.51% decline over the past three years compared to a 36.32% increase in the Sensex. The high institutional holdings at 40.24% may suggest confidence from more knowledgeable investors, but the current trends indicate that the stock is struggling in the short term against both its own historical performance and the broader market.